SPA
STLN

Sherbrooke Park Advisers’s Starling Oncology STLN Stock Holding History

Sherbrooke Park Advisers’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,656
Closed -$51.1K – 516
2025
Q3 		$51.1K Buy
+14,656
New +$50.2K 0.02% 489

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sherbrooke Park Advisers's STLN Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Starling Oncology (STLN) in Q4 2025, closing a stake of 14,656 shares — an estimated $51.1K sold.

Sherbrooke Park Advisers first reported a position in STLN in Q3 2025 and held it in 1 quarter. The position peaked at $51.1K in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Starling Oncology position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 14,656 Starling Oncology shares in Q4 2025, an estimated $51.1K.
  • Sherbrooke Park Advisers first reported a position in Starling Oncology in Q3 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Starling Oncology position peaked at $51.1K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.